Tybost (cobicistat)
- Region
- 🇪🇺 EU
- Active substance
- cobicistat
- Company
- Gilead Sciences Ireland UC
- Status
- Authorised
- Therapeutic area
- HIV Infections
- EU approval
- Thu 19 Sep 2013
- Application
- EMEA/H/C/002572
- ATC
- V03AX03
- Official record
- www.ema.europa.eu
Indication
Tybost is indicated as a pharmacokinetic enhancer of atazanavir 300 mg once daily or darunavir 800 mg once daily as part of antiretroviral combination therapy in human immunodeficiency virus-1 (HIV-1) infected adults and adolescents aged 12 years and older: weighing at least 35 kg co?administered with atazanavir or weighing at least 40 kg co?administered with darunavir.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇺🇸 Prezcobix Approved · Janssen Prods
- 🇪🇺 Symtuza Authorised · Janssen-Cilag International
- 🇪🇺 Rezolsta Authorised ·
- 🇪🇺 Genvoya Authorised · Gilead Sciences Ireland UC
- 🇪🇺 Stribild Authorised · Gilead Sciences Ireland UC
- 🇪🇺 Evotaz Authorised · Bristol-Myers Squibb Pharma EEIG
Follow Tybost
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.